Reuters logo
BRIEF-J&J's Janssen announces Imbruvica as the first approved treatment for chronic graft-versus-host disease granted by Health Canada priority review
October 30, 2017 / 11:47 AM / 23 days ago

BRIEF-J&J's Janssen announces Imbruvica as the first approved treatment for chronic graft-versus-host disease granted by Health Canada priority review

Oct 30 (Reuters) - Johnson & Johnson

* Janssen Inc. announces Imbruvica® (ibrutinib) as the first approved treatment for chronic graft-versus-host disease (CGVHD) granted by Health Canada priority review

* Janssen - Health Canada has approved Imbruvica (ibrutinib) for treatment of patients with steroid dependent, refractory chronic graft-versus-host disease​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below